RECRUITING

Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)

Conditions

Multi-Drug Resistant Organism Colonization Multi-Drug Resistant Organism Fecal Microbiota Transplant Antibiotic Resistance Long-Term Care Facilities

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO). REACT is designed to assess the safety and efficacy of MT administered to subjects colonized with a MDRO. The overarching hypothesis is that MT can reduce MDRO colonization with safety that is comparable to observation.

Official Title

Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy

Quick Facts

Study Start:2025-01-13

Study Completion:2025-12

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06321536

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Be able (or have available a Legal Authorized Representative who is able) to understand and sign a written informed consent document. 2. Be at least 18 years old at the time of consent. 3. Be able to comply with all study protocol requirements, including able to receive MT as retention enema or via enteral feeding tube and be available for the duration of the study follow up. 4. Be colonized with a target MDRO (CRE, VRE, ESBL, MDR Pseudomonas) as detected by bacterial culture of stool or peri-rectal swab (collected in companion APPS facility prevalence sampling protocol). 5. Be able to discontinue or complete planned courses of antibiotics, probiotics, and other microbiota restoration therapies by Day -1 and not resume until after Day 28. 6. The effects of the MT on the developing human fetus are unknown. For this reason, persons of child-bearing potential (POCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. 7. Agree to refrain from receptive anal intercourse until the last biological specimen (stool sample or peri-rectal swab) is collected (Day 28).	1. Are pregnant, breastfeeding, lactating, or planning a pregnancy during study duration (through 4 weeks after the last dose of investigational product, or MT), if POCBP. 2. Have known uncontrolled intercurrent illness(es): 1. Symptomatic congestive heart failure 2. Acute coronary syndrome 3. Cardiac arrhythmia 4. Untreated in-situ colorectal cancer 5. Toxic megacolon 6. Ileus 7. Positive stool studies without completion of treatment course (including ova and parasites, Salmonella spp, Shigella, Campylobacter, and other enteropathogens). 8. other acute illness that in the opinion of the investigator could affect the safety of the participant or make study data uninterpretable. 3. Are on systemic antibiotics for any reason other than treatment of recent MDRO infection or clear anticipated need for antibiotics during the follow up period that cannot be rescheduled (e.g. fluoroquinolone prophylaxis for percutaneous nephrostomy tube exchange, prolonged antibiotic course for endocarditis). Participants must complete the planned antibiotic course by study Day -1. 4. Have a compromised immune system, defined as: 1. AIDS with CD4+ T-cell count \<200 and detectable HIV viral load on most recent assay. 2. Absolute neutrophil count (ANC) \<1,000 neutrophils / mL on day of enrollment. 3. Active malignancy requiring intensive induction chemotherapy, radiotherapy, or biologic treatment within 2 months prior to enrollment. 4. History of hematopoietic cell transplantation, either allogeneic or autologous in the last 1 year. 5. Have a history of significant food allergy that led to anaphylaxis or hospitalization. 6. Have a life expectancy of 24 weeks or less 7. Have any condition that, in the opinion of the investigator, might interfere with study objectives or limit compliance with study requirements, including but not limited to: 1. Known active intravenous drug or alcohol abuse 2. Uncontrolled psychiatric illness 3. Social situations (e.g. incarceration) 8. Received an interventional agent (drug, device, or procedure) within 28 days prior to enrollment.

Inclusion Criteria

Exclusion Criteria

1. Be able (or have available a Legal Authorized Representative who is able) to understand and sign a written informed consent document.
2. Be at least 18 years old at the time of consent.
3. Be able to comply with all study protocol requirements, including able to receive MT as retention enema or via enteral feeding tube and be available for the duration of the study follow up.
4. Be colonized with a target MDRO (CRE, VRE, ESBL, MDR Pseudomonas) as detected by bacterial culture of stool or peri-rectal swab (collected in companion APPS facility prevalence sampling protocol).
5. Be able to discontinue or complete planned courses of antibiotics, probiotics, and other microbiota restoration therapies by Day -1 and not resume until after Day 28.
6. The effects of the MT on the developing human fetus are unknown. For this reason, persons of child-bearing potential (POCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
7. Agree to refrain from receptive anal intercourse until the last biological specimen (stool sample or peri-rectal swab) is collected (Day 28).

1. Are pregnant, breastfeeding, lactating, or planning a pregnancy during study duration (through 4 weeks after the last dose of investigational product, or MT), if POCBP.
2. Have known uncontrolled intercurrent illness(es):
1. Symptomatic congestive heart failure
2. Acute coronary syndrome
3. Cardiac arrhythmia
4. Untreated in-situ colorectal cancer
5. Toxic megacolon
6. Ileus
7. Positive stool studies without completion of treatment course (including ova and parasites, Salmonella spp, Shigella, Campylobacter, and other enteropathogens).
8. other acute illness that in the opinion of the investigator could affect the safety of the participant or make study data uninterpretable.
3. Are on systemic antibiotics for any reason other than treatment of recent MDRO infection or clear anticipated need for antibiotics during the follow up period that cannot be rescheduled (e.g. fluoroquinolone prophylaxis for percutaneous nephrostomy tube exchange, prolonged antibiotic course for endocarditis). Participants must complete the planned antibiotic course by study Day -1.
4. Have a compromised immune system, defined as:
1. AIDS with CD4+ T-cell count \<200 and detectable HIV viral load on most recent assay.
2. Absolute neutrophil count (ANC) \<1,000 neutrophils / mL on day of enrollment.
3. Active malignancy requiring intensive induction chemotherapy, radiotherapy, or biologic treatment within 2 months prior to enrollment.
4. History of hematopoietic cell transplantation, either allogeneic or autologous in the last 1 year.
5. Have a history of significant food allergy that led to anaphylaxis or hospitalization.
6. Have a life expectancy of 24 weeks or less
7. Have any condition that, in the opinion of the investigator, might interfere with study objectives or limit compliance with study requirements, including but not limited to:
1. Known active intravenous drug or alcohol abuse
2. Uncontrolled psychiatric illness
3. Social situations (e.g. incarceration)
8. Received an interventional agent (drug, device, or procedure) within 28 days prior to enrollment.

Contacts and Locations

Study Contact

Deepti Suchindran, PhD

CONTACT

404-727-9193

deepti.rao.suchindran@emory.edu

Michael Woodworth, MD

CONTACT

michael.holmes.woodworth@emory.edu

Principal Investigator

Michael Woodworth, MD

PRINCIPAL_INVESTIGATOR

Emory University

Study Locations (Sites)

Emory University Hospital

Atlanta, Georgia, 30322

United States

Collaborators and Investigators

Sponsor: Emory University

Michael Woodworth, MD, PRINCIPAL_INVESTIGATOR, Emory University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-13

Study Completion Date2025-12

Study Record Updates

Study Start Date2025-01-13

Study Completion Date2025-12

Terms related to this study

Keywords Provided by Researchers

Multi-Drug Resistant Organism
Fecal Microbiota Transplant
Antibiotic Resistance
Long-Term Care Facilities

Additional Relevant MeSH Terms

Multi-Drug Resistant Organism Colonization